The protein moiety of the Brucella Omp19 lipoprotein, co-administered as oral adjuvant, induces a Th1 immune response.

IBAÑEZ, ANDRES; CORIA, LORENA; PASQUEVICH, KARINA; BARRIONUEVO, PAULA; DELPINO M. VICTORIA; GIAMBARTOLOMEI, GUILLERMO; CASSATARO, JULIANA

New Delhi

Simposio; Keystone Symposia on Molecular Cell Biology Meeting: Malnutrition, Gut-Microbial Interactions and Mucosal Immunity to Vaccines (T1).; 2011

Bill & Melinda Gates Foundation

Previous results demonstrate that the protein moiety of the Brucella Omp19 lipoprotein (U-Omp19) administered by the oral route has self-adjuvant properties. These prompt us to study its mucosal adjuvant capacity using as a model antigen ovalbumin (OVA). For this purpose mice were immunized orally with OVA, U-Omp19+OVA, or choleric toxin (CT)+OVA. By flow cytometry we determined that the percentage of CD4+ and CD8+ T cells expressing α4β7 integrin increased in those mesenteric lymph nodes from U-Omp19+OVA (CD4+ α4β7+: 7,7%; CD8+ α4β7+:12,16%) and CT+OVA (7,15%; 16,46%) in comparison with OVA (0,74%; 1,64%) immunized mice. We also observed a significant delayed type hypersensitivity (DTH) response to OVA injection in U-Omp19+OVA (Δ=0,11mm, P